Bernstein initiates Incyte stock coverage with concerns on growth

Bernstein initiated Incyte at Market Perform with a $99 price target, only modestly above the $97.39 share price, citing uncertainty over growth after Jakafi loses exclusivity in 2028. The firm said Jakafi represented 60% of fiscal 2025 revenue and sees peak risk-adjusted sales of $6.7B in fiscal 2028, falling to $3.9B by fiscal 2040, while replacement efforts like Monjuvi appear insufficient. Offset by positives, Incyte beat quarterly consensus, gained FDA approval for Jakafi XR, and continues pipeline and AI partnerships, but the note remains cautious on long-term growth.

Analysis

The setup is less about near-term fundamentals and more about duration risk: the market is still paying for a visible cash engine while the street is now openly modeling an erosion path that starts well before exclusivity loss. That creates a classic multiple-compression regime if the company cannot prove a post-Jakafi growth slope within the next 12-18 months, because biotech multiples tend to re-rate on the next dominant revenue leg, not on distant optionality. The fact that the balance sheet is clean matters defensively, but it does not offset the market’s tendency to assign almost zero value to long-dated pipeline promises until late-stage data de-risks them.

The real second-order issue is competitive sequencing: once investors accept that lifecycle management will not fully bridge the gap, every incremental dollar of Opzelura or newer assets becomes less about growth and more about how much of the eventual revenue cliff can be cushioned. That shifts the stock’s behavior from a “quality growth” name to a binary catalyst tape, where trial design, registrational timing, and label breadth matter more than quarterly beats. In that regime, positive earnings can be faded if they do not change the forward launch calendar, while any delay in trial visibility can trigger disproportionate downside.

The contrarian angle is that the market may already be discounting too much of the patent-expiry anxiety before the core franchise actually rolls over. If management can demonstrate even modest acceleration from non-Jakafi assets over the next two reporting cycles, the current valuation could defend as a cash-flow compounder rather than a melting-ice-cube story. The key is whether new pipeline disclosure converts from scientific promise into a concrete capital allocation narrative with measurable milestones; without that, the multiple likely stays capped despite operational strength.

Key Decisions for Investors

• Avoid initiating fresh long exposure in INCY ahead of the next catalyst window; use a 6-12 month horizon and wait for clearer registrational trial details on INCA033989 before paying for pipeline optionality.
• For existing longs, consider reducing size on strength and running a tighter trailing stop into the next earnings cycle; upside is likely capped while downside accelerates if the market starts discounting the 2028 cliff more aggressively.
• Relative-value idea: long a late-stage dermatology/oncology platform name with nearer-dated growth visibility versus short INCY as a duration hedge; the spread should work if investors continue preferring clearer post-patent revenue bridges.
• Use call spreads rather than stock if bullish: buy 6-9 month bull call spreads only on a material pullback, since the main risk is multiple compression rather than outright business deterioration over the next few quarters.
• If INCA033989 gets a clean trial-design update, consider a tactical long into the readout sequencing, but take profits quickly on any data-driven pop because the market will likely price execution risk well before approval.